QL1706: clinical trials recruiting now

Phase breakdown

Conditions being studied

Recruiting trials involving QL1706

• A Study of Neoadjuvant QL1706 in Participants With Untreated dMMR/MSI-H Resectable Colon Cancer
  NCT06686576 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• First-line Regimen With QL1706 Plus Chemo ± Bev in PDAC Patients
  NCT06313970 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast Cancer
  NCT07180160 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 1 location
• Perioperative Study of Iparomlimab and Tuvonralimab in Resectable NSCLC
  NCT06897046 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• QL1706 Plus Chemotherapy +/- Bevacizumab in 1L Treatment of R/mTNBC
  NCT06786026 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: Female · 1 location
• QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer
  NCT06951997 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• QL1706 for the Neoadjuvant Treatment of HR+/HER2- Breast Cancer
  NCT06967103 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location

Common questions

How many recruiting trials involve QL1706?

7 recruiting trials across 11 conditions.

Is this list of trials complete?

No. For the full record, search ClinicalTrials.gov.